Altus Pharmaceuticals Appoints John M. Sorvillo, Ph.D. as Vice President of Business Development.CAMBRIDGE, Mass. -- Altus Pharmaceuticals Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ALTU), a biopharmaceutical company developing and commercializing oral and injectable in·ject·a·ble adj. Capable of being injected. Used of a drug. n. A drug or medicine that can be injected. protein therapeutics for patients with gastrointestinal and metabolic disorders, announced today that John M. Sorvillo, Ph.D. has been appointed Vice President of Business Development. In this position, Dr. Sorvillo will be responsible for establishing partnerships for Altus' late stage products and seeking development collaborations for its early stage and preclinical programs. "We believe that John will be a tremendous asset to growing and expanding Altus' business," said Sheldon Berkle, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Altus. "He has a proven track record in corporate development, deal making, and in- and out-licensing, and we are pleased that he brings this strong background to Altus." Dr. Sorvillo has over 20 years of business and scientific experience in the biotechnology industry. Before joining Altus, Dr. Sorvillo was Chief Executive Officer of Bionaut Pharmaceuticals. Dr. Sorvillo also spent nine years as Vice President of Business Development at ArQule, where he was responsible for establishing corporate collaborations with pharmaceutical companies. While serving for 10 years at OSI Pharmaceuticals OSI Pharmaceuticals, Inc. is an American pharmaceutical company based in Long Island, New York with facilities in Colorado, New Jersey and the United Kingdom. They specialize in the discovery and development of molecular targeted therapies, and are listed in the NASDAQ (formerly Oncogene oncogene Gene that can cause cancer. It is a sequence of DNA that has been altered or mutated from its original form, the proto-oncogene (see mutation). Proto-oncogenes promote the specialization and division of normal cells. Science), Dr. Sorvillo held a variety of positions leading up to his last position as Vice President and General Manager, Research Products Division. Dr. Sorvillo was a postdoctoral fellow at Memorial Sloan Kettering Cancer Center. He holds a Ph.D. in Immunology from the New York University New York University, mainly in New York City; coeducational; chartered 1831, opened 1832 as the Univ. of the City of New York, renamed 1896. It comprises 13 schools and colleges, maintaining 4 main centers (including the Medical Center) in the city, as well as the Medical Center, Sackler Institute of Biomedical Sciences, and a B.A. in Biology from the City University of New York The City University of New York (CUNY; acronym: IPA pronunciation: [kjuni]), is the public university system of New York City. , Hunter College. About Altus Pharmaceuticals Inc.: Altus Pharmaceuticals, headquartered in Cambridge, MA is a biopharmaceutical company focused on the development and commercialization of oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders. The Company's website is http://www.altus.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion